Wednesday, 18 November 2026NewsWorldBusinessTech
Latest

ECDC Warns Superbugs Kill 35,000 Annually in Europe

“the antibiotics doctors usually reach for first are failing against serious hospital infections,” said Dr Marc-Alain Widdowson, head of health security at WHO/Europe.

Antimicrobial resistance kills over 35,000 people annually across the European Union, Iceland, and Norway. Drug-resistant bacterial infections are surging across Europe. The European Centre for Disease Prevention and Control warned on Wednesday, 18 November 2026, about this toll. That mortality matches the combined toll of influenza, tuberculosis, and HIV.

Escalating Superbug Crisis in Europe

Bloodstream infections have emerged as a primary hazard. The region missed reduction targets for both Klebsiella pneumoniae and Escherichia coli. Healthcare facilities are struggling to contain multidrug-resistant strains.

The estimated EU incidence of antibiotic-resistant E. coli infections grew by 16.4 percent between 2019 and 2025. That growth overshot a target to achieve a 10 percent reduction from the 2019 baseline.

Infections caused by Klebsiella pneumoniae rose by an estimated 72 percent between 2019 and 2025. That missed the target of a 5 percent reduction. In 2025, the incidence of these infections stood at 3.75 cases per 100,000 people.

Europe risks returning to ‘pre-antibiotic era’ amid growing threat of drug-resistant superbugs
Photo: Euronews.com

Christian Giske, head of ECDC’s Antimicrobial Resistance and Healthcare-Associated Infections Section, said that many of these strains show genetic links indicating direct transmission alongside advanced resistance mechanisms. Laboratory tests show that certain strains have developed resistance to nearly all available antibiotics, including newer drugs, with mortality rates ranging from 40% to 70%.

The ECDC report cautioned that a lack of potent antimicrobial drugs could plunge us back into the ‘pre-antibiotic era’. This makes vital medical interventions such as cancer chemotherapy, intensive care, and organ transplantation extremely difficult or unfeasible to carry out safely.

Cyprus Leads European Surge in Resistant Infections

National infection rates and consumption levels vary widely across the European region. Cyprus recorded a 716 percent surge in antibiotic-resistant K. pneumoniae infections, reaching 21.29 cases per 100,000 people, alongside a 276 percent increase in resistant E. coli bloodstream infections.

When antibiotics stop working: Europe's growing superbug threat — euronews

Romania reported 18.66 resistant infections per 100,000 population. Greece recorded 16.28 per 100,000 people. Hungary saw resistant K. pneumoniae infections rise by 1,622 percent, with Croatia and Bulgaria recording increases of 409 percent and 356 percent respectively.

More than 70 percent of the health burden of antimicrobial resistance in Europe stems from healthcare-associated infections involving multidrug-resistant bacteria acquired during hospital stays. Giske said that proper infection control can prevent half of this burden through measures such as hand hygiene, protective equipment, single rooms, and thorough environmental cleaning.

Similar protocols successfully lowered bloodstream infections caused by MRSA by 19 percent in 2025 compared to 2019 levels, exceeding the EU target.

Resistant Acinetobacter bloodstream infection rates have dropped by nearly half from the peak levels recorded during the COVID-19 pandemic in 2021. Yet, an analysis of 110,538 operations published in the journal Anesthesiology revealed that air sterilization and purification units in operating theaters failed to decrease surgical site infections, patient deaths, or postoperative complications.

Patients running out of options as antibiotics stop working against common infections — SignalsMonitor
Photo: signalsmonitor.com

Clinicians Face Dwindling Antibiotic Options as Resistance Spreads

When frontline antibiotics fail, clinicians turn to stronger medications like carbapenems. Widdowson explained the narrowing therapeutic window.

“When those stop working too, what’s left is mostly a small group of last-resort drugs that are often expensive and not available in every country,” Widdowson said. “Each time one of these lines of defence falls, patients move closer to having no good options at all. That matters, because people whose first antibiotic doesn’t work against their infection are more likely to die in hospital.”

Surveillance gaps compound the clinical challenge. The World Health Organization reported that 16 of 51 analyzed countries still lack a standardized national approach and coordination.

In hospitals where clinicians draw few blood samples to identify pathogens, medical teams “have to choose an antibiotic without knowing which will work,” according to the agency. That leaves health systems planning without reliable data on where resistance spreads.

“Better testing would help on both fronts, giving patients the right drug sooner and countries a clearer view of the threat,” WHO said.

The European Centre for Disease Prevention and Control, an EU agency founded in 2004 and headquartered in Solna, Sweden, was set up in record time after the 2003 SARS outbreak confirmed the urgency of an EU-wide public health institution. It became operational in May 2005 and runs the scientific journal Eurosurveillance.

Its Disease Programmes include Antimicrobial Resistance and Healthcare-Associated Infections, the section that produced Wednesday’s warning. The centre also collaborates with the European Medicines Agency on vaccine safety and public health emergencies.

Readers evaluating these findings should consult qualified health professionals regarding any medical concerns or antibiotic treatments, as this reporting does not constitute clinical guidance. That mortality matches the combined toll of influenza, tuberculosis, and HIV.